Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis
NCT07757841 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2026-08-11
Summary
An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Conditions
- Allergic Bronchopulmonary Aspergillosis
- Severe Asthma
- ABPA
Interventions
- DRUG
-
Tezepelumab
210 mg (1.91 mL) Subcutaneous Solution
Sponsors & Collaborators
-
Qianfoshan Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-01
- Primary Completion
- 2027-06-30
- Completion
- 2027-12-31
Countries
- China
Study Locations
More Related Trials
-
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
NCT01321827 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
NCT01632540 ·Status: COMPLETED
-
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
NCT07399665 ·Status: RECRUITING
-
Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy
NCT01479205 ·Status: COMPLETED
-
Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps
NCT07046117 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide
NCT00312312 ·Status: UNKNOWN ·Phase: NA
-
Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.
NCT01134757 ·Status: COMPLETED ·Phase: NA
-
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
NCT06998095 ·Status: NOT_YET_RECRUITING
-
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
NCT02440009 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)
NCT06189742 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
NCT05063981 ·Status: COMPLETED
-
INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION
NCT07415278 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
NCT00857779 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
NCT00044824 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
NCT00044811 ·Status: COMPLETED ·Phase: PHASE3
-
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
NCT00641212 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
NCT06771934 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity
NCT00584051 ·Status: TERMINATED
-
Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
NCT00791102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety Study of Olopatadine Nasal Spray
NCT00578331 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
NCT02075008 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
NCT00712920 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
NCT01277341 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
NCT06046391 ·Status: COMPLETED ·Phase: PHASE2